Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Profit After Tax: 2009-2024

Historic Profit After Tax for Corcept Therapeutics (CORT) over the last 12 years, with Dec 2024 value amounting to $141.2 million.

  • Corcept Therapeutics' Profit After Tax fell 58.34% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.1 million, marking a year-over-year decrease of 25.18%. This contributed to the annual value of $141.2 million for FY2024, which is 33.04% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Profit After Tax of $141.2 million as of FY2024, which was up 33.04% from $106.1 million recorded in FY2023.
  • Corcept Therapeutics' 5-year Profit After Tax high stood at $141.2 million for FY2024, and its period low was $101.4 million during FY2022.
  • Moreover, its 3-year median value for Profit After Tax was $106.1 million (2023), whereas its average is $116.3 million.
  • In the last 5 years, Corcept Therapeutics' Profit After Tax fell by 9.86% in 2022 and then spiked by 33.04% in 2024.
  • Corcept Therapeutics' Profit After Tax (Yearly) stood at $106.0 million in 2020, then climbed by 6.13% to $112.5 million in 2021, then dropped by 9.86% to $101.4 million in 2022, then rose by 4.66% to $106.1 million in 2023, then skyrocketed by 33.04% to $141.2 million in 2024.